Clinical Study on the Safety of SAFIL® MESH
Launched by AESCULAP AG · Jun 23, 2021
Trial Information
Current as of June 26, 2025
Completed
Keywords
ClinConnect Summary
The study design is a retrospective case-note series of patients that have undergone reinforcement of soft tissues with Safil® Mesh after abdominal wall surgery or other fascial defects between the period January 2019 - November 2020
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients operated between January 2019 - November 2020 for abdominal wall surgery or other fascial defects and received Safil® Mesh
- Exclusion Criteria:
- • No exclusion criteria have been set.
About Aesculap Ag
Aesculap AG is a prominent global medical device manufacturer specializing in surgical instruments, implants, and innovative healthcare solutions. With a rich history rooted in excellence and innovation, Aesculap AG is dedicated to advancing surgical practices through cutting-edge technology and a commitment to improving patient outcomes. The company collaborates with healthcare professionals and institutions to conduct clinical trials that evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of quality and performance. Through its rigorous research and development initiatives, Aesculap AG aims to contribute significantly to the field of medicine and enhance the standards of surgical care worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Salamanca, , Spain
Galdakao, Bizkaia, Spain
Patients applied
Trial Officials
Izaskun Badiola Bergara, Dr.
Principal Investigator
Hospital Galdakao-Usansolo
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials